Capricor Therapeutics Inc (NASDAQ:CAPR) Sees Significant Decrease in Short Interest

kopsource · Aug 18, 2022 21:32

Capricor Therapeutics Inc (NASDAQ:CAPR – Get Rating) saw a large drop in short interest in the month of July. As of July 31st, there was short interest totalling 358,500 shares, a drop of 9.1% from the July 15th total of 394,500 shares. Based on an average daily volume of 113,700 shares, the days-to-cover ratio is currently 3.2 days.

Capricor Therapeutics Trading Up 3.1 %

NASDAQ CAPR opened at $5.26 on Thursday. Capricor Therapeutics has a 52 week low of $2.56 and a 52 week high of $5.85. The company has a 50 day moving average price of $4.38 and a 200 day moving average price of $4.03.

Get Capricor Therapeutics alerts:

Capricor Therapeutics (NASDAQ:CAPR – Get Rating) last issued its quarterly earnings results on Wednesday, August 10th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.25) by ($0.04). During the same period last year, the business earned ($0.21) earnings per share. As a group, equities analysts forecast that Capricor Therapeutics will post -1.17 EPS for the current year.

Wall Street Analyst Weigh In

Separately, StockNews.com upgraded Capricor Therapeutics to a "sell" rating in a research note on Monday, May 23rd.

Insiders Place Their Bets

In other Capricor Therapeutics news, Director David B. Musket sold 28,215 shares of the company's stock in a transaction on Wednesday, June 29th. The stock was sold at an average price of $3.77, for a total value of $106,370.55. Following the completion of the sale, the director now directly owns 12,747 shares in the company, valued at approximately $48,056.19. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, Director David B. Musket sold 17,775 shares of the business's stock in a transaction that occurred on Monday, June 27th. The shares were sold at an average price of $4.44, for a total value of $78,921.00. Following the completion of the transaction, the director now owns 40,962 shares of the company's stock, valued at $181,871.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director David B. Musket sold 28,215 shares of the company's stock in a transaction on Wednesday, June 29th. The stock was sold at an average price of $3.77, for a total value of $106,370.55. Following the sale, the director now owns 12,747 shares of the company's stock, valued at approximately $48,056.19. The disclosure for this sale can be found here. 9.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Capricor Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Selective Wealth Management Inc. purchased a new stake in shares of Capricor Therapeutics during the first quarter worth about $732,000. Vanguard Group Inc. increased its stake in Capricor Therapeutics by 5.6% during the 1st quarter. Vanguard Group Inc. now owns 1,020,998 shares of the biotechnology company's stock valued at $3,502,000 after purchasing an additional 54,260 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Capricor Therapeutics by 54.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 148,768 shares of the biotechnology company's stock valued at $510,000 after purchasing an additional 52,611 shares in the last quarter. Bailard Inc. purchased a new position in shares of Capricor Therapeutics in the second quarter worth $104,000. Finally, UBS Group AG grew its holdings in shares of Capricor Therapeutics by 326.0% during the second quarter. UBS Group AG now owns 29,352 shares of the biotechnology company's stock valued at $102,000 after buying an additional 22,462 shares during the last quarter. 9.49% of the stock is currently owned by hedge funds and other institutional investors.

Capricor Therapeutics Company Profile

(Get Rating)

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.